NCT00892762View on ClinicalTrials.gov

Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

PHASE3CompletedINTERVENTIONAL

Enrollment

434

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Open Angle GlaucomaOcular Hypertension

Interventions

DRUG

Travoprost APS 40 micrograms/ml eye drop solution

non-BAK (benzalkonium chloride) medication

DRUG

Latanoprost 50 micrograms/ml eye drop solution

BAK-preserved medication

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alcon Research

INDUSTRY